Evidence map›Paper›PMID 29796164›Full record

ArticleOncotarget2018

Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.

Hayley Pye, Mohammed Adil Butt, Laura Funnell, Halla W Reinert, Ignazio Puccio, Saif U Rehman Khan, Savvas Saouros, Jared S Marklew, Ioanna Stamati, Maryam Qurashi and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Hayley PyeDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Mohammed Adil ButtDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Laura FunnellDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Halla W ReinertDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Ignazio PuccioDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Saif U Rehman KhanDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Savvas SaourosAntikor BioPharma, Stevenage, UK.
Jared S MarklewAntikor BioPharma, Stevenage, UK.
Ioanna StamatiAntikor BioPharma, Stevenage, UK.
Maryam QurashiDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Rehan HaidryUpper Gastrointestinal Service, University College London Hospitals NHS Foundation Trust, London, UK.
Vinay SehgalDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Dahmane OukrifDepartment of Pathology, University College London, London, UK.
Michael GandyDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Hayley C WhitakerDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Manuel Rodriguez-JustoDepartment of Pathology, University College London, London, UK.
Marco NovelliDepartment of Pathology, University College London, London, UK.
Rifat HamoudiDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Gokhan YahiogluAntikor BioPharma, Stevenage, UK.
Mahendra P DeonarainDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
Laurence B LovatDepartment for Tissue and Energy, Division of Surgery and Interventional Science, University College London, London, UK.
University College London · GBBioPharm (United Kingdom) · GBStevenage Bioscience Catalyst · GBUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Sharjah · AE

Funding

Medical Research Council MC_PC_13036
6 · The paper itself

Abstract

Early oesophageal adenocarcinoma (OA) and pre-neoplastic dysplasia may be treated with endoscopic resection and ablative techniques such as photodynamic therapy (PDT). Though effective, discrete areas of disease may be missed leading to recurrence. PDT further suffers from the side effects of off-target photosensitivity. A tumour specific and light targeted therapeutic agent with optimised pharmacokinetics could be used to destroy residual cancerous cells left behind after resection. A small molecule antibody-photosensitizer conjugate was developed targeting human epidermal growth factor receptor 2 (HER2). This was tested in an

Indexed as

antibody drug conjugateHER2heterogeneityoesophageal adenocarcinomaphotodynamic therapy

Identifiers

PMID29796164
PMCPMC5955430
OpenAlexW2800147251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.